EPO was demonstrated to protect against the VEGF-induced permeability of the blood-brain barrier (BBB) through restoring the tight junction proteins and VE-cadherin in experimental diabetic retinopathy and in vitro bovine model (22, 23). Here, VEGFA is linked to diabetic retinopathy.